Epstein-Barr virus (EBV) is an important cancer causing virus. Cancer associated with EBV account for approximately 1.5% of all cancers, and represent 1.8% of all cancer deaths worldwide. EBV reactivation plays an important role in the development of EBV-related diseases and is closely related with patients' survival and clinical stages of EBV-related cancers. The therapy regarding to EBV-related cancers is very urgent, especially in endemic areas. Generating oxidative stress is a critical mechanism by which host cells defend against infection by virus. In addition, ROS-mediated oxidative stress plays a significant but paradoxical role acting as a "double-edged sword" to regulate cellular response to radiation, which is the main therapy strategy for EBV-related cancers, especially nasopharyngeal carcinoma. Therefore, in this review we primarily discuss the possible interplay among the oxidative stress, EBV lytic reactivation and radioresistance. Understanding the role of oxidative stress in EBV lytic reactivation and radioresistance will assist in the development of effective strategies for prevention and treatment of EBV-related cancers.
EBV, the first known human tumor virus, is a member of the g-herpesviruses that infects roughly 95% of adult individuals worldwide. EBV has been found to be associated with a diverse range of tumors of both lymphoid and epithelial origin including Burkitt's lymphoma (BL), Post-transplant lymphoproliferative disease (PTLD), Hodgkin lymphoma (HL), NK and T cell lymphomas, gastric carcinoma (GC) and nasopharyngeal carcinoma (NPC). 1 Like all herpesviruses, EBV establishes a latent infection that is periodically reactivated into the productive lytic cycle. 2 The latent-lytic switch is tightly controlled by both cellular and viral factors. Following reactivation, the lytic genes of EBV are expressed in a temporally regulated manner. The first ones transcribed are the viral immediate-early lytic genes, BZLF1 and BRLF1. They encode the transcription factors, Zta and Rta, respectively. Neither BZLF1 nor BRLF1 is expressed in latently infected cells due to silencing by multiple cellular transcriptional repressors. Subsequently, the Z and R proteins activate both their own and one another's promoters to greatly amplify their lytic-inducing effects. They then cooperatively activate the promoters of early lytic genes that encode the viral replication proteins. Following viral genome replication, the late viral genes are expressed. The latter encode structural proteins required for viral genome encapsulation into infectious virion particles.
Various lines of evidence indicate that lytic induction of EBV can occur in EBV-related diseases. [3] [4] [5] [6] In our laboratory, observed the immediate-early and early lytic genes, BZLF1 and BMRF1, are expressed in NPC and lymphoma tissues, suggesting that active lytic reactivation is involved in the pathogenesis NPC and lymphoma patients. 3 Besides, BZLF1 mRNA was detected in various specimens (saliva, plasma, PBMC) of patients with EBV-induced infectious mononucleosis, also indicating the presence of lytic reactivation in EBVrelated diseases. 4 Moreover, Tsai et al. isolated an EBV strain M81 from a Chinese patient with NPC, which has unusually high levels of spontaneously replication activities, suggesting the enhanced viral replication observed in NPC patients. 5 In addition, in a recent study of 700 EBV-immortalized lymphoblastoid cell lines that were characterized for host and viral transcriptome and epigenome, viral lytic genes were coexpressed with cellular cancer-associated pathways, including pathways involved in B cell chronic lymphocytic leukemia, interferon-alpha (INFa), WNT, and B cell receptor signaling, Arvey et al. which suggested that EBV lytic reactivation occurred and played a role in oncogenesis of EBV (1) tumors. 6 Research findings have documented that EBV lytic reactivation is a major risk factor for the development of EBV-related diseases. They mainly contribute to the induction of genome instability, the counteraction of host immune responses, the resistance of cell death and the promotion of tumor development, progression and invasiveness. 1 First, induce genome instability. Several reports have demonstrated after recurrent reactivation of EBV, the degree of genome instability was significantly enhanced. [7] [8] [9] Also, EBV lytic genes BZLF1,
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BGLF4
11 and BGLF5 12 can induce genome instability. Most notably, one latest research reported EBV lytic replication had a marked influence on the genetic stability and identified a new mechanism in EBV induced cancer. 13 EBV virions that generate in the process of lytic replication can induce aneuploidy and centrosome amplification, associated with chromosomal instability, thereby conferring a risk to non-replicating cells and for development of tumors. Patients infected with viruses that strongly replicate are likely to be at higher risk. Second, evade immune surveillance. Several lytic genes encode immune evasion proteins, including BNLF2a 14 (inhibits the transporter of antigen processing), BILF1 15 (induces major histocompatibility complex (MHC) class I internalization and degradation) and BGLF5 16 (mediates host shut-off), and these proteins play an important role in avoiding immune destruction. Third, resist cell death. In the process of EBV lytic reactivation, EBV encodes several anti-apoptotic proteins such as BHRF1 17 and BARF1, 18 which usually play important roles in gaining resistance to apoptosis. Fourth, contribute to tumor development, progression and invasiveness. Hong et al. in their study demonstrated lytically infected cells in EBV-positive tumors could contribute to tumor formation through the release of paracrine growth factors 19 as well as angiogenesis factors (VEGF) and this process may potentially contribute to viral pathogenesis. 20 In addition, Fang et al. revealed that after recurrent EBV reactivation, the invasiveness and tumorigenicity of NPC cells were enhanced. 8 Also, NPC patients with high levels of the BZLF1 transactivator protein ZEBRA/IgG titer group were found to have distant lung and liver metastases and a poor survival rate. 21 Finally, induced activation of EBV contributes to carcinogenesis. It has been reported several lifestyle factors can induce transformation of EBV from the latent to the lytic stage and contribute to NPC occurrence, such as salted fish or preserved food. 22 Besides, cigarette smoking can induce EBV lytic reactivation and increase the risk of NPC. 23 In addition, several cellular stresses were also reported to contribute to EBV reactivation and lead to an increase of NPC risk, such as oxidative stress, hypoxia and inflammation. 7 The above-mentioned function of EBV lytic reactivation indicated that the lytic cycle plays an important role in the pathogenesis of EBV-related diseases.
Oxidative stress is an important molecular mechanism in EBV lytic reactivation Generating oxidative stress is a critical mechanism by which host cells defend against infection by pathogenic microorganisms. 24 Recent evidence showed increased levels of ROS during in vitro [25] [26] [27] [28] [29] [30] [31] and in vivo EBV infection as well as clinically in EBV-associated patients. [32] [33] [34] [35] In vitro, EBV infection can induce an increase in malondialdehyde (MDA) levels and decreases in catalase and superoxide dismutase (SOD) activities. 31 This is the first evidence of oxidative stress in human cells as a response to EBV inoculation. Similarly, the effects of inducing the EBV viral lytic cycle on the oxidant/antioxidant balance in three lymphoblastoid cell lines indicated that oxidative stress was a consequence of lytic cycle induction. 25 Additionally, a positive correlation was observed between BZLF1 and antioxidant enzyme genes expression which also confirmed a role of EBV lytic reactivation in oxidative stress. 26 Notably, reactive oxygen signaling can distinguish EBV-positive versus EBV negative Burkitt's lymphoma based on the finding that elevated levels of ROS are observed in EBVpositive tumors but not in EBV-negative tumors. 27 This demonstrated that EBV infection could cause the generation of ROS, which leads to high levels of oxidative stress in EBVpositive cells or tumors. On the other hand, oxidative stress inducers, such as H 2 O 2 or FeSO 4 , can cause EBV lytic cycle induction as demonstrated by BZLF1 gene expression 28 Moreover, various drugs that induce or inhibit EBV lytic reactivation also act by generating oxidative stress. 29, 30 Thus, a vicious cycle could be initiated whereby reactivation of EBV and ROS production amplify each another.
In addition, a growing number of reports have shown an association between in vivo EBV infection and oxidative stress.
Over-expression of iNOS and the accumulation of 8-OHdG, critical biomarkers of oxidative stress, were found in NPC patients. 32, 33 Huang et al. detected the serum 8-OHdG using ELISA in NPC patients and found that all cases of NPC were positive for 8-OHdG and therefore, 8-OHdG is proposed as a potential biomarker for evaluating the risk of NPC. 34 Su et al. observed decreased SOD activity in NPC that is consistently associated with EBV. 35 These observations indicate that NPC biopsies present a high level of oxidative stress and the screening of several biomarkers, such as iNOS, show that NPC tissues and patients exhibit high levels of oxidative stress. 34 Pre-clinical and clinical evidence indicate the oxidative stress is involved in EBV lytic reactivation and it has even been proposed that EBV (1) tumors is reactive oxygen-driven tumors. 36 Thus, oxidative stress might play a decisive role in carcinogenesis in EBV-induced cancers and serve as a pharmacologic target for cancer prevention and treatment Furthermore, several EBV-encoded products, including EBNA1, LMP1 and EBER are associated with oxidative stress.
EBNA1. The EBV latent viral antigen, Epstein-Barr Nuclear Antigen 1 (EBNA1), is the only nuclear EBV protein expressed in both latent and lytic modes of infection and is known to be consistently expressed across all EBV-associated malignancies. Accumulating evidence has shown that EBNA1 expression is closely associated with oxidative stress. Cells expressing EBNA1 had an approximate 7-fold higher level of ROS compared to the same cells lacking EBNA1. 37 The promoting effect of EBNA1 on genomic instability and telomere dysfunction both occurred through the induction of oxidative stress. 38, 39 Possible mechanisms by which EBNA1 could induce ROS, include increasing levels of oxidases (e.g., NOX1 and NOX2) or affecting the levels of antioxidant enzymes, such as SOD1, peroxiredoxin 1, peroxiredoxin 6 or glutathione S-transferase. 38, 39 LMP1. Latent membrane protein 1 (LMP1), a primary oncoprotein encoded by EBV, is critical for EBV-induced B-cell transformation and is also abundantly expressed during the lytic cycle of viral replication. Several studies have indicated that LMP1 is likely a candidate for inducing ROS. Cerimele et al. used a tetracycline-inducible epithelial cell line to determine whether LMP1 can induce ROS generation. They found that the addition of tetracycline led to a significant decrease in LMP1expression, as well as ROS production, thus implicating LMP1 as a major inducer of ROS. 27 The C-terminal activating regions (CTAR) of LMP1 interact with members of the tumor necrosis factor (TNF) receptor-associated factor (TRAF) families. 40 Whereas activation of ROS has not been associated previously with LMP1 signaling, TRAF activation by other ligands has been shown to induce ROS signaling, thereby providing a potential mechanism for LMPmediated ROS induction. 41 On the other hand, Chen et al. demonstrated that EBV infection of B lymphocytes could induce the accumulation of ROS, and quenching ROS was associated with selective down-regulation of viral LMP1. Analysis of the mechanism by which high levels of ROS support LMP1 expression revealed a selective inhibition of viral microRNAs that target the LMP1 transcript. 42 Thus, LMP1 was demonstrated to induce the generation of ROS, and the oxidative stress microenvironment could also affect the expression of LMP1 by targeting viral microRNAs.
Other associated EBV-encoded products. EBV-encoded RNA (EBER), which induces interleukin (IL)-10 and IL-10 has been implicated in the activation of mitochondrial ROS. 27 
ROS-Mediated Oxidative Stress in Radiation Therapy: A Double-Edged Sword
Among the multiple EBV-associated human maligancies, NPC is highly radiosensitive and radiotherapy is the primary and only curative treatment for NPC. In centers where modern radiation technology is available, intensity-modulated radiotherapy (IMRT) is the preferred method compared with conventional two-dimensional (2 D) radiotherapy and three-dimensional (3 D) radiotherapy. 43 Despite the excellent local control with modern radiotherapy, distant failure remains a key challenge. 44 In addition, resistance to radiation therapy remains a major clinical problem, also leading to a poor outcome for NPC patients. Several specific signaling pathways contribute to cells gaining resistance against ionizing radiation (IR). 45 Among these signaling pathways, ROS play a significant but paradoxical role acting as a "double-edged sword'' to regulate cellular response to radiation.
ROS is a critical mediator of IR-induced cell killing
ROS are clearly key intermediates in the toxicity against tumors induced by radiotherapy. When ROS levels rise beyond a tolerable limit inside tumor cells, apoptosis is initiated and ROSinduced cell death may be either direct or indirect. 46 High levels of ROS cause a cluster of lesions to form within DNA that are difficult to repair and lead directly to cell death. Besides DNA damage, other major targets of radiation, such as cell membranes and organelles can be structurally and functionally impaired and thus might contribute to cell cycle arrest and apoptosis. Indirect cell death involves altered cellular homeostasis and modified signaling pathways ultimately leading to apoptosis. In addition, ROS are also reported to be important factors in the IR-induced bystander effect. 47 Emerging evidence suggests that the bystander effect has a role in genomic instability and carcinogenesis. 48 
ROS is a critical regulator of IR-resistant pathways
Tumor cell stemness and radioresistance. In radiation oncology, cancer stem cells (CSCs) have become a hot research focus. Basically, these cells are classically resistant to radiation therapy and might contribute to treatment failure and tumor relapse. 49 One mechanism of the higher radioresistance of CSCs compared to non-CSCs might be associated with an increased potential of defense against ROS. Diehn et al. reported that similar to normal tissue stem cells (NTCs), subsets of CSCs in some tumors contain lower levels of ROS and enhanced ROS defenses compared to their non-tumorigenic progeny. Lower ROS levels result in less DNA damage caused by IR, which might contribute to tumor radioresistance. 50 In addition, CD24 is a key marker for breast CSCs and knocking down expression of CD24 decreases radiation-induced oxidative stress and genomic instability corresponding with radiation resistance in cancer cells. 51 A strategy to overcome low levels of ROS within CSCs may be a useful method for improving local and systemic oncologic therapies.
Antioxidant enzymes and radioresistance. Radioresistant variant clones (RRCs) exhibit highly activated antioxidant enzymes compared to parent cells following radiation. For example, SOD, catalase, glutathione peroxidase (GPX), and glutathione reductase (GR) were activated up to 5-fold in RRCs in glioblastoma compared to parent cells after radiation. 52 In addition, peroxiredoxins (Prxs), members of a family of peroxidases, play crucial roles in maintaining redox balance and are also involved in ROS adaptive radioresistance pathways. PrxII is reportedly significantly up-regulated in radioresistant cancer cells and functions to reduce the intracellular levels of ROS. This results in increased resistance of breast cancer cells to ionizing radiation, suggesting that PrxII confers radioresistance by eliminating the ROS induced by IR. Therefore, PrxII is also a potential key player in the increased resistance of cancer cells to ionizing radiation. 53 Inflammation and radioresistance. Inflammation plays a pivotal role in modulating responsiveness of tumors to radiation. In particular, nuclear factor-kappa B (NF-jB) and hypoxia inducible factor 1 (HIF-1) play a crucial role in radiation-induced inflammatory responses embedded in a complex inflammatory network. Evidence has demonstrated that these inflammatory signaling pathways are involved in ROS-associated radioresistance. NF-jB. The involvement of NF-jB in ROS-mediated radioresistance occurs mainly by regulation of manganesecontaining superoxide dismutase (MnSOD), a powerful antioxidant enzyme, is encoded by the SOD2 gene and is a target gene of NF-jB. 54 Normally, the regulation of MnSOD by NF-jB promotes protection against radiation and overexpression of MnSOD enhances antioxidant radioprotection effects by reducing irradiation-induced apoptosis. 55 MnSOD over-expression can also restore cellular resistance to TNF-ainduced cell death. Moreover, MnSOD was shown to protect against ROS-induced injury in MnSOD-knockout mice. 56 Therefore, MnSOD-mediated redox regulation is essential for protecting cells from IR-mediated toxicity and MnSOD seems to be an important NF-jB effector gene in radioresistance. HIF-1. Besides NF-jB, HIF-1 is a critical regulator of cellular responses to hypoxia and is crucially involved in radioresistance of tumors. Hsieh et al. has reported that cycling hypoxia triggered ROS production in U87 glioma cells and ROS-mediated HIF-1a activation is a crucial mechanism involved in hypoxia-induced radioresistance in U87 gliomas. 57 MicroRNA and radioresistance. MicroRNAs can modulate gene expression by degrading or inhibiting the translation of target mRNAs. 58 Yang et al. reported that the knockdown of miR-153 could up-regulate its target gene, Nrf2, and the enhanced Nrf2 expression increased the transcription of GPx1 and decreased the levels of ROS leading to cellular radioresistance. This suggested that miR-153 over-expression decreased radioresistance of cells by targeting the Nrf2/GPx1/ROS pathway, indicating that microRNAs are also involved in ROS-associated resistance pathways. 59 The Interplay of EBV Lytic Reactivation and Radioresistance EBV-encoded LMP1 affects EBV lytic reactivation and contributes to radioresistance LMP1 affects EBV lytic reactivation acting by different mechanisms. Emerging reports have demonstrated different roles of LMP1 in EBV lytic reactivation. On one hand, the expression of LMP1 contributes to EBV lytic reactivation. Inducible expression of LMP1 during the viral lytic cycle plays a vitally important role in virus production because loss of LMP1 severely impaired virus release into culture supernatant fractions, resulting in poor infection efficiency. 60 In addition, LMP1 can be induced by ectopic expression of Rta in both epithelial and B-lymphoid cells, and its expression is associated with the spontaneous virus reactivation in EBVinfected 293 cells. 61 We also found that over-expression of LMP1 induces EBV lytic reactivation in different EBVpositive cells (unpublished). On the other hand, several groups have reported that LMP1 can inhibit lytic cycle progression. By using the P3HR1-c16 cell line as a model, Prince et al. found that LMP1 interferes with the EBV lytic cycle in three distinct ways. One occurs through NF-jB and the others two are distinct NF-jB-independent mechanisms. One involves the cytosolic C-terminal activating regions and the other involves the transmembrane region of LMP1. 62 In addition, LMP1 could inhibit EBV lytic reactivation and may assist in establishing viral latency in B cells. 63 In summary, EBV utilizes LMP1 for dual purposes during its life cycle. First, in latently infected B lymphocytes, steady-state expression of LMP1 is critical for maintaining transformation status. Second, at the onset of the virus production cycle, the strong induction of LMP1 enables efficient virus release from cells. Therefore, LMP1 is apparently one of the most important viral proteins required for EBV's life cycle in its survival and transmission from host to host.
LMP1 promotes therapeutic resistance through multiple virussensing axes in NPC in vitro and in vivo. Several groups have demonstrated a consistent phenomenon showing that low expression of LMP1 in NPC cells could inhibit cell proliferation and metastasis, promote apoptosis, and enhance radiosensitivity of NPC. 64 The researchers found that a potential mechanism occurs through the interference signaling pathways, which are launched by LMP1. These include the NF/jB/ATM axis, 65 Akt/hTERT axis, 66 JNKs/HIF/1/VEGF axis, 67 DNA/PK/AMPK axis 68 and PI-3 K/Akt/c-Myc/HK2, 69 each of these signaling axes can affect cell survival, telomerase activity, tumor angiogenesis, DNA damage response and tumor glycolysis, which are processes that are very important for tumor development. In addition, LMP1 reportedly can induce cancer stem-like cell characteristics that might be one way to contribute toradioresitance. 70 Furthermore, several reports have indicated that LMP1 could regulate its target miRNA (miR-155) that confers radioresistance. 71 Based on these findings, LMP1 is projected to be a biomarker for enhancing the radiosensitivity of NPC. 72 
EBV-encoded products resist cell death and might confer radioresistance
Apoptosis is the prevalent form of cell death underlying radiation therapy. Lack of response to apoptosis by tumor cells is one of the main mechanisms leading to radioresistance. Tumor cells can adopt several ways to resist cell apoptosis and ensure their survival. 45 In the process of EBV infection, EBV encodes several anti-apoptotic products such as BHRF1, BARF1, EBNA1, ERERs and miR-BARTs, which usually play important roles in gaining resistance to apoptosis.
BHRF1. BHRF1 is a component of the restricted early antigen complex of the EBV lytic cycle, encoding a 17 kDa putative transmembrane protein with both sequence and functional homology to the Bcl-2 protooncogene. 73 BHRF1 is believed to be a pro-survival molecule that exerts antiapoptotic effects based on the evidence showing that knockdown of BHRF1 expression resulted in increased cell death. 74, 75 The underlying mechanism of BHRF1's ability to block apoptosis occurs mainly by binding to a limited amount of Bim, which is a pro-apoptotic protein.
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BARF1. The BARF1 is considered to be a lytic EBV protein that is expressed early during lytic infection. A high level of BARF1 expression is detectable in NPC. 76 BARF1 reportedly functions as a viral oncogene that up-regulates anti-apoptotic Bcl-2 and stimulates host cell growth and survival. 77 BARF1 knockdown up-regulates the expression of pro-apoptotic proteins and down-regulates the expression of anti-apoptotic proteins. 18 Moreover, BARF1 promotes cancer cell survival by increasing the Bcl-2 to Bax ratio. 22 Based on the current evidence, the expression of BHRF1 or BARF1 during EBV lytic reactivation might increase their ability to function as survival factors to resist apoptosis and contribute to radioresistance.
Other associated EBV-encoded products. EBNA1 was reported to confer resistance to apoptosis in EBV-positive Blymphoma cells through up-regulation of apoptosis suppressor protein, survivin. 78 Besides, EBERs could also confer resistance to apoptosis via binding to PKR and inhibition of its phosphorylation in Burkitt's lymphoma. 79 In addition, prevention of apoptosis is a major function of miR-BARTs in EBV (1) epithelial cancers. The expression of miR-BART5 and multiple miR-BARTs in cluster 1 can indirectly impair apoptosis by targeting the pro-apoptotic proteins PUMA and Bim, respectively. 80, 81 Preventive and Therapeutic Implications EBV-related parameters as potential preventive and therapeutic markers
In endemic areas, screening has been the most promising tool to improve the early detection rate and to eventually reduce mortality from NPC. Currently, EBV VCA/IgA (belong to EBV lytic phase) and EBNA1/IgA tests by ELISA have been used for mass screening to detect NPC in southern China (NCT00941538, Clinical Trails.gov). 82 In addition, accumulating research data supports the use of plasma or serum EBV DNA as a tumor marker. Plasma or serum EBV DNA is gradually being adopted in clinical applications and has been shown to be correlated with tumor burden, 83 TNM stage, 84 response to therapy, [85] [86] [87] and survival in NPC patients. 83, [85] [86] [87] [88] Most notably, two phase 3 trials are underway, in which patients are randomly assigned to adjuvant regimens of differing intensities depending on whether EBV DNA is detectable after chemoradiotherapy (NCT02135042 and NCT00370890, Clinical Trails.gov). 43 In addition, NP brush/swab sampling combined with EBV DNA detection has been a valuable supplement in the diagnosis of NPC because of its high sensitivity and specificity. 89 Therefore, detection of EBV based on EBV-related parameters might be one of the most important approaches for the prevention and personalized treatment of EBV-associated cancers.
Moreover, there is an interesting paper reported cigarette smoking could induce EBV lytic reactivation as demonstrated by the expression of immediate-early transcriptional activators Zta and Rta, and increased transcriptional expression levels of proteins in the lytic phase. It is might be a potential novel mechanism of NPC etiology. 23 Therefore, it is reasonable to suppose the smokers might be more likely to become susceptible population of NPC. The mass screening based on the EBV lytic reactivation should be conducted in these populations in endemic areas. In addition, cigarette cessation programs should be advocated for the primary prevention of NPC, especially in NPC endemic areas.
Antioxidant compounds as potential preventive and therapeutic drugs
As noted earlier, NPC patients are characterized by high levels of oxidative stress based on the detection of 8-OHdG and iNOS. In addition, many other kits could also be used to detect oxidative status, such kits that measure MDA or the levels of reduced and oxidized glutathione (i.e., redox state). Scavenging ROS might be a good way for NPC prevention and therapy. Ma et al. reported N-acetyl L-cysteine (NAC), a Food and Drug Administration (FDA)-approved inhibitor of ROS generation, effectively suppresses tumorigenesis in a Kaposi's sarcomaassociated herpesvirus (KSHV)-driven KS mouse model. 90, 91 We also found that NAC could effectively inhibit EBV lytic reactivation (data not published). In addition, oral hairy leukoplakia (OHL) is also a kind of disease which is caused in part by lytic infection of epithelial cells with EBV. Gentian violet, another FDA approved over-the-counter medication, can be used as a method to OHL treatment, which is also due to its inhibitory effect on ROS. 92 These suggested that antioxidants could be therapeutic and chemopreventive targets for EBV, providing opportunities for low cost drug development for virus-induced cancer treatment.
In addition, natural compounds, normally found in foods, are gaining increased attention due to their proposed cancerpreventive and therapeutic activities and potential greater safety compared to synthetic compounds. 45 In therapy of EBVassociated cancers, curcumin, resveratrol and EGCG reportedly show great potential. One reason might be due to their obvious antioxidant activities, which might contribute to decreasing the level of oxidative stress before or during treatment. [93] [94] [95] Also, the potential antioxidant activities might assist them to have better biological and radioprotective effects for normal cells. 45, [96] [97] [98] [99] Another reason might be their abilities to inhibit EBV lytic reactivation 29, 30, 100 and enhance the efficiency of radiation. 45, [96] [97] [98] [99] The biological activities of these antioxidant natural compounds might assume them to be effective strategies in the prevention and treatment of EBV-associated cancers. Specifically, one phase 2/3 trial are underway on studying the effect of EGCG on EBV reactivation in remission patients with NPC (NCT01744587, Clinical Trails.gov), 43 which demonstrated the great potential of antioxidants in NPC therapy. In addition, it is worth nothing that reactive oxygen inhibition is often insufficient to kill or regress a tumor cell by itself in clinical trials, so it is suggested the researchers to develop the sequential therapy of ROS blockade followed by chemotherapy or radiation in the treatment of cancer. 36 
Conclusions and Perspectives
EBV lytic reactivation plays an important role in the development of EBV-related diseases and is strongly associated with the patients' response to therapy, and prognosis. In this review, we discussed the role of oxidative stress in EBV lytic reactivation and radioresistance. However, the in-depth mechanisms associated with the induction of EBV lytic reactivation by oxidative stress are not clear. Elucidating these mechanisms could be very helpful in the therapy of EBVrelated cancers. Moreover, the precious role of EBV lytic reactivation in the pathogenesis of NPC in vivo also remains unclear and is urgently needed to perform study on the degree of lytic replication in established tumors for expounding its consequences for pathogenesis. In addition, in NPC therapy, the radioresistance is a challenge which cannot be neglected. The EBV lytic reactivation may play some undiscovered roles in this process, so there is a clear need for larger and more concerted studies to document these unknown issues.
It is cheerful that great progress has been made in identifying biomarkers related to EBV infection such as VCA-IgA and EBV DNA in recent years. The application of these biomarkers in personalized treatment and precision medicine might have great potential in the future therapy of EBV-associated cancers. Also, it has been reported EBV is an important vaccine target for cancer prevention 101 and the discovery of an EBV vaccine based on lytic parameters might be a good option for the prevention and therapy of EBV-associated diseases.
In addition, natural compounds are emerging that are deemed to be putative radiosensitizers. The future perspectives lie in identifying more of these compounds and elucidating their mechanism of action, which might help to develop efficient and ideal drugs for improving cancer radiotherapy.
